Chen, L., Chow, A., Ma, W., Coker, C., Gu, Y., Canoll, P., Kandpal, M., Hibshoosh, H., Biswas, A. K., & Acharyya, S. (2025). A new, immunocompetent brain-metastatic mouse model of HER2-positive breast cancer. Clinical & Experimental Metastasis, 42(3). https://doi.org/10.1007/s10585-025-10343-4

Jhaveri, K. L., Accordino, M. K., Bedard, P. L., Cervantes, A., Gambardella, V., Hamilton, E., Italiano, A., Kalinsky, K., Krop, I. E., Oliveira, M., Schmid, P., Saura, C., Turner, N. C., Varga, A., Cheeti, S., Hilz, S., Hutchinson, K. E., Jin, Y., Royer-Joo, S., … Juric, D. (2024). Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 42(33), 3947–3956. https://doi.org/10.1200/jco.24.00110

Sompuram, S. R., Vani, K., Ryan, L., Johnson, C., Szabolcs, M., Peruyero, L., Balaton, A., Pierrot, S., Joseph, L., Pilichowska, M., Naber, S., Goldsmith, J., Green, S., & Bogen, S. A. (2023). Validation of Linear Range HER2/Estrogen Receptor/Progesterone Receptor IHControls for Daily Quality Assurance. American Journal of Clinical Pathology, 159(3), 274–282. https://doi.org/10.1093/ajcp/aqac163

Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x